{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Chen M"],"funding":["Open Fund of the CAS Key Laboratory of Regenerative Biology, Guangdong Provincial Key Laboratory of Stem Cell and Regenerative Medicine","Science and Technology Planning Project of Guangdong Province, China","National Key Research and Development Program of China Stem Cell and Translational Research","Science Foundation for Young Teachers of Wuyi University","National Natural Science Foundation of China"],"pagination":["e13319"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9628231"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["55(11)"],"pubmed_abstract":["<h4>Objectives</h4>Transplantation of neural progenitor cells (NPCs) derived from human-induced pluripotent stem cells (hiPSCs) is one of the promising treatment strategies for motor neuron diseases (MNDs). However, the inefficiency in committed differentiation of NPCs in vivo limits its application. Here, we tried to establish a potential therapeutic strategy for MNDs by in vivo directional differentiation of hiPSCs engineered with motor neuron (MN) specific transcription factors and Tet-On system.<h4>Materials and methods</h4>We engineered hiPSCs with three MN-specific transcription factors and Tet-On system. The engineered cells were directly transplanted into immunodeficient mice through subcutaneous, intra-spinal cord and intracerebroventricular injections. Following doxycycline (Dox)"],"journal":["Cell proliferation"],"pubmed_title":["Inducible motor neuron differentiation of human induced pluripotent stem cells in vivo."],"pmcid":["PMC9628231"],"funding_grant_id":["82001974","2019TD05","2017YFA0105103","2020B1212060052"],"pubmed_authors":["Zheng X","Li C","Zhang K","Chen M","Zhou R","Tang C","Ang S","Wei Y","Zhou X","Lan T","Rosa A","Zou Q","Wang X","Lai L"],"additional_accession":[]},"is_claimable":false,"name":"Inducible motor neuron differentiation of human induced pluripotent stem cells in vivo.","description":"<h4>Objectives</h4>Transplantation of neural progenitor cells (NPCs) derived from human-induced pluripotent stem cells (hiPSCs) is one of the promising treatment strategies for motor neuron diseases (MNDs). However, the inefficiency in committed differentiation of NPCs in vivo limits its application. Here, we tried to establish a potential therapeutic strategy for MNDs by in vivo directional differentiation of hiPSCs engineered with motor neuron (MN) specific transcription factors and Tet-On system.<h4>Materials and methods</h4>We engineered hiPSCs with three MN-specific transcription factors and Tet-On system. The engineered cells were directly transplanted into immunodeficient mice through subcutaneous, intra-spinal cord and intracerebroventricular injections. Following doxycycline (Dox)","dates":{"release":"2022-01-01T00:00:00Z","publication":"2022 Nov","modification":"2025-04-26T20:47:26.673Z","creation":"2025-04-06T16:32:40.845Z"},"accession":"S-EPMC9628231","cross_references":{"pubmed":["35943218"],"doi":["10.1111/cpr.13319"]}}